Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA advisory committee recommends approval of miglustat in Niemann-Pick disease

This article was originally published in Scrip

Executive Summary

The US FDA's endocrinologic and metabolic drugs advisory committee has virtually urged the agency to ignore its own legislative mandate and give Actelion Pharmaceuticals ethe green light to market miglustat for the genetic lysosomal storage disorder Niemann-Pick disease, type 3 (NP-C). On January 12th, the panel voted 10 to three that the risk-benefit profile in the safety and efficacy data presented by Actelion justified approval. But that majority included four committee members who had voted "no" to the question of whether Actelion had presented "substantial efficacy" of efficacy - the legal standard the FDA is supposed to use. On that issue, six members found there was substantial evidence of efficacy, while seven members said there was not.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts